ArticleAnnals of biomedical engineering2026
A Virtual Trial to Identify Cardiovascular Biomarkers for Differentiating Diabetic and Hypertensive Kidney Disease.
Article in Annals of biomedical engineering, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
purposeA diagnostic challenge in the management of chronic kidney disease (CKD) is distinguishing diabetic kidney disease (DKD) from hypertensive kidney disease (HKD) in patients with coexisting diabetes mellitus (DM) and hypertension (HTN), because accurate diagnosis often depends on renal biopsy as a reference standard. This study proposes a modeling approach to identify cardiovascular biomarkers for differentiating DKD from HKD.
methodsAn existing whole-body circulation model of the vascular tree was extended with a detailed renal circulation network to predict biomarkers measured at different locations. The model parameterized sex, age, and disease factors and was used to conduct virtual clinical trials that identified individual and combined biomarkers for DKD-HKD differentiation. Biomarkers were identified with univariate and multivariate analysis and characterized with the area under the receiver operating characteristic curve (AUC).
resultsResults show that the strongest individual biomarker that is commonly used in clinical practice is pulsatility index (PI) measured in the main renal artery, with an AUC of 0.87. Among all evaluated two-biomarker combinations, PI and resistive index (RI) measured in the same artery achieved the highest classification performance (AUC 0.94). In comparison, the highest performance among three-biomarker combinations (AUC 0.96) is achieved by mean blood flow rate, systolic blood flow rate, and diastolic flow rate.
conclusionThis modeling work suggests that cardiovascular biomarkers can assist in differentiating DKD and HKD, and proposes specific hypotheses that form a strong rationale for targeted clinical trials. If confirmed, these methods could enable non-invasive assessment of renal vascular alterations associated with DKD and HKD, reducing reliance on kidney biopsies for diagnostic evaluation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.